Article Information
History
- August 10, 2018.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Daisy X. Ji1,
- Katherine J. Chen1,
- Naofumi Mukaida2,
- Igor Kramnik3,
- K. Heran Darwin4 and
- Russell E. Vance1,5,6,*
- 1Division of Immunology and Pathogenesis, Department of Molecular and Cell Biology, University of California, Berkeley, CA 94720 USA
- 2Division of Molecular Bioregulation, Cancer Research Institute, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan
- 3The National Emerging Infectious Diseases Laboratory, Department of Medicine (Pulmonary Center), and Department of Microbiology, Boston University School of Medicine, Boston, MA 02118 USA
- 4Department of Microbiology, New York University School of Medicine, New York, New York, 10016 USA
- 5Cancer Research Laboratory, University of California, Berkeley, CA 94720 USA
- 6Howard Hughes Medical Institute, University of California, Berkeley, CA 94720 USA
Posted August 10, 2018.
Interleukin-1 receptor antagonist mediates type I interferon-driven susceptibility to Mycobacterium tuberculosis
